Success Stories: From Lab to Clinic: Researcher Wins NIW for Cancer Immunotherapy Advances

Client’s Testimonial:

“Thank you so much for your help-it was only with your help that I was able to receive my EB2-NIW I-140 approval so smoothly.”

On September 10^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Staff Scientist in the Field of Tumor Immunology (Approval Notice).

General Field: Tumor Immunology

Position at the Time of Filing: Staff Scientist

Country of Origin: Taiwan

State of Residence at the Time of Filing: Oklahoma

Approval Notice Date: September 10^th, 2025

Processing Time: 1 month, 3 days (Premium Processing Requested)

Case Summary:

Cancer remains one of the greatest public health challenges of our time, and the burden is especially severe for patients with treatment-resistant and rare cancers. These cases often lack effective therapies, leading to poor clinical outcomes and high healthcare costs.

An immunology researcher has dedicated his career to addressing this need by creating advanced preclinical cancer models that evaluate the efficacy and immune responses of novel immunotherapies. His work involves cancer vaccines, antibody-drug conjugates (ADCs), and rational combination strategies designed to improve treatment outcomes and expand options for patients with aggressive cancers. By optimizing these models, his research bridges the gap between laboratory discovery and clinical application, making therapies safer, more effective, and more widely accessible.

The significance of this research has already been recognized at the national level. His work has been supported by the Department of Defense’s Rare Cancers Research Program and Lung Cancer Research Program, as well as by the National Cancer Institute’s My Pediatric and Adult Rare Tumor Network (MyPART) and HealthBanks Biotech. Peers in the field have also praised his contributions.

As one expert explained, “[Client]’s work addresses this issue by identifying new targets for therapeutics and vaccines and determining the role of numerous cellular components in the proliferation of cancer within the body, thus helping U.S. clinicians develop more effective treatments and halt the rising rates of cancer diagnoses and deaths across America.”

Beyond securing competitive funding and endorsements, the researcher has built a solid record of scholarly achievement: 11 peer-reviewed journal articles (4 first-authored), 4 conference abstracts, 1 first-authored preprint, and at least 17 peer reviews for scientific journals. His work has been cited 260 times, further demonstrating its influence on the field of tumor immunology.

With this combination of impactful research, growing recognition, and proven qualifications, his petition for an EB-2 NIW was approved. NAILG carefully prepared and presented the case, resulting in this successful outcome. With his NIW approval, the researcher is now positioned to continue developing cutting-edge immunotherapies that can transform treatment strategies and improve outcomes for patients facing some of the most difficult cancer diagnoses.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.